He is leading translational research aimed to improve patient care by accelerating the development and delivery of personalised healthcare, including personalised therapies and diagnostics, applied to neurodegenerative, neuroimmunological and cerebrovascular disorders, particularly on the immune-mediated mechanisms and the amyloid-related imaging abnormalities (ARIA) in the pathogenesis of both rare diseases, i.e. Cerebral Amyloid Angiopathy-related inflammation (CAA-ri), and during immunotherapy trials of Alzheimer’s disease.
He has more than 10 years experience in the discovery and validation of diagnostic, prognostic and therapeutic biomarkers and tools.
Dr Piazza is the founding Member and Coordinator of the inflammatory Cerebral Amyloid Angiopathy and Alzheimer’s disease βiomarkers International Network (iCAβ), a World-Wide Consortium involving 35 leading Centers of Excellence on AD and CAA from 12 different Countries, established in 2012
The validation of biomarkers of ARIA, as well as the definition of clinico-therapeutic recommendations to guide CAA and AD immunotherapy trials, is the main goal of the the biomarkARIA Research Project (P.I. Dr. Piazza) and iCAB International Network , the largest worldwide effort aimed at deciphering the pathogenetic mechanisms of CAA-ri and ARIA in a translational and cooperatively-open design between Academia and pharma companies.